Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLEDYL vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular c AMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of bronchial asthma,Treatment of reversible bronchospasm associated with chronic bronchitis and emphysema
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life: 7-9 hours (non-smoking adults); 4-5 hours (smokers); 20-30 hours (premature neonates, hepatic cirrhosis, CHF); clinical context: dose adjustment required for smokers and hepatic impairment.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal excretion of theophylline metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid), with 10% unchanged drug; biliary/fecal < 5%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
40% bound, primarily to albumin.
55–65% bound to plasma proteins, primarily albumin.
Vd: 0.5 L/kg (0.3-0.7 L/kg); clinical meaning: distributes into total body water, with higher volume in premature neonates.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral immediate-release: 100%; oral sustained-release: 85-95%; rectal: 90-100% (variable).
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: administer 200 mg every 12-24 hours; consider monitoring serum theophylline levels.
No dose adjustment required for renal impairment.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: contraindicated or reduce dose by 90% with close monitoring of serum levels.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not recommended for children under 6 years; for children 6-12 years: 10-12 mg/kg/day divided every 6-8 hours; for adolescents: same as adult dosing, adjusted based on serum levels.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at 200 mg twice daily; adjust based on serum theophylline levels (target 5-15 mcg/m L); monitor for toxicity due to reduced clearance.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Risk of toxicity due to narrow therapeutic index; serum levels should be monitored carefully.,Use with caution in patients with peptic ulcer, cardiac arrhythmias, seizure disorders, or hyperthyroidism.,May exacerbate gastroesophageal reflux disease.,Concomitant use with other xanthine derivatives may increase toxicity.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or choline salicylate,Active peptic ulcer disease,Seizure disorder (unless appropriately controlled)
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
High-fat meals may increase absorption; avoid charbroiled meats which decrease theophylline clearance. Consistent caffeine intake should be maintained to avoid fluctuations in drug levels.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Choledyl (theophylline oxtriphylline) is a xanthine derivative. In pregnancy, theophylline crosses the placenta. First trimester: No consistent evidence of major malformations, but some studies suggest a small increased risk of congenital heart defects. Second and third trimesters: Fetal tachycardia, jitteriness, and hypoglycemia can occur with maternal high levels. Neonatal withdrawal and respiratory distress have been reported.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk. Milk-to-plasma ratio is approximately 0.6-0.7. Concentrations in milk can reach 60-70% of maternal serum levels. Infant exposure may cause irritability, jitteriness, and poor feeding. Use with caution, monitor infant for adverse effects, and consider timing doses after breastfeeding.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
During pregnancy, theophylline clearance may decrease due to reduced hepatic metabolism and increased plasma volume. Dose adjustments are often required, especially in the third trimester. Monitor serum levels closely, as clearance can decrease by 20-30%. Dose may need to be reduced by 20-30% to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels, requiring dose increase.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Choledyl (oxtriphylline) is a bronchodilator; monitor theophylline levels due to narrow therapeutic index. Avoid in patients with peptic ulcer or seizure disorders. Cautious use with hepatic impairment or heart failure. Dose adjustment needed with cimetidine, ciprofloxacin, or macrolides due to decreased clearance.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take with food if GI upset occurs.,Avoid excessive caffeine (coffee, tea, cola) as it may increase side effects.,Do not crush or chew sustained-release forms.,Seek medical attention for rapid heartbeat, seizures, or severe nausea.,Report signs of toxicity: persistent vomiting, confusion, or palpitations.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLEDYL vs AEROLATE SR, answered by our medical review team.
CHOLEDYL is a Bronchodilator that works by Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular c AMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLEDYL and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLEDYL is: 200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLEDYL and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLEDYL is classified as Category C. Choledyl (theophylline oxtriphylline) is a xanthine derivative. In pregnancy, theophylline crosses the placenta. First trimester: No consistent evidence of major malformations, but. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.